130 related articles for article (PubMed ID: 8101873)
1. Effect of antiretroviral therapy on the cerebrospinal fluid of patients seropositive for the human immunodeficiency virus.
Gulevich SJ; McCutchan JA; Thal LJ; Kirson D; Durand D; Wallace M; Mehta P; Heyes MP; Grant I
J Acquir Immune Defic Syndr (1988); 1993 Sep; 6(9):1002-7. PubMed ID: 8101873
[TBL] [Abstract][Full Text] [Related]
2. The effect of zidovudine treatment on serum neopterin and beta 2-microglobulin levels in mildly symptomatic, HIV type 1 seropositive individuals.
Bass HZ; Hardy WD; Mitsuyasu RT; Taylor JM; Wang YX; Fischl MA; Spector SA; Richman DD; Fahey JL
J Acquir Immune Defic Syndr (1988); 1992; 5(3):215-21. PubMed ID: 1346807
[TBL] [Abstract][Full Text] [Related]
3. Cerebrospinal fluid neopterin and beta 2-microglobulin levels in neurologically asymptomatic HIV-infected patients before and after initiation of zidovudine treatment.
Hagberg L; Norkrans G; Andersson M; Wachter H; Fuchs D
Infection; 1992; 20(6):313-5. PubMed ID: 1293049
[TBL] [Abstract][Full Text] [Related]
4. Cerebrospinal fluid neopterin levels in 159 neurologically asymptomatic persons infected with the human immunodeficiency virus (HIV-1): relationship to immune status.
Lucey DR; McGuire SA; Abbadessa S; Hall K; Woolford B; Valtier S; Butzin CA; Melcher GP; Hendrix CW
Viral Immunol; 1993; 6(4):267-72. PubMed ID: 7909441
[TBL] [Abstract][Full Text] [Related]
5. Markers of immune stimulation in the cerebrospinal fluid during HIV infection: a longitudinal study.
Gisslén M; Chiodi F; Fuchs D; Norkrans G; Svennerholm B; Wachter H; Hagberg L
Scand J Infect Dis; 1994; 26(5):523-33. PubMed ID: 7855550
[TBL] [Abstract][Full Text] [Related]
6. Increase of tryptophan in serum and in cerebrospinal fluid of patients with HIV infection during zidovudine therapy.
Fuchs D; Gisslén M; Larsson M; Norkrans G; Hagberg L; Wachter H
Adv Exp Med Biol; 1996; 398():131-4. PubMed ID: 8906255
[TBL] [Abstract][Full Text] [Related]
7. The effect on human immunodeficiency virus type 1 RNA levels in cerebrospinal fluid after initiation of zidovudine or didanosine.
Gisslén M; Norkrans G; Svennerholm B; Hagberg L
J Infect Dis; 1997 Feb; 175(2):434-7. PubMed ID: 9203666
[TBL] [Abstract][Full Text] [Related]
8. Inter-relationships between quinolinic acid, neuroactive kynurenines, neopterin and beta 2-microglobulin in cerebrospinal fluid and serum of HIV-1-infected patients.
Heyes MP; Brew BJ; Saito K; Quearry BJ; Price RW; Lee K; Bhalla RB; Der M; Markey SP
J Neuroimmunol; 1992 Sep; 40(1):71-80. PubMed ID: 1387655
[TBL] [Abstract][Full Text] [Related]
9. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1.
Fahey JL; Taylor JM; Detels R; Hofmann B; Melmed R; Nishanian P; Giorgi JV
N Engl J Med; 1990 Jan; 322(3):166-72. PubMed ID: 1967191
[TBL] [Abstract][Full Text] [Related]
10. Effect of zidovudine on cerebrospinal fluid in patients with HIV infection and acute neurological disease.
Hagberg L; Andersson M; Chiodi F; Fuchs D; Svennerholm B; Wachter H; Norkrans G
Scand J Infect Dis; 1991; 23(6):681-5. PubMed ID: 1815328
[TBL] [Abstract][Full Text] [Related]
11. Alpha 1-acid glycoprotein levels in AIDS patients before and after short-term treatment with zidovudine (ZDV).
Oie S; Jacobson MA; Abrams DI
J Acquir Immune Defic Syndr (1988); 1993 May; 6(5):531-3. PubMed ID: 8097790
[No Abstract] [Full Text] [Related]
12. Expansion of neopterin and beta 2-microglobulin in cerebrospinal fluid reaches maximum levels early and late in the course of human immunodeficiency virus infection.
Bogner JR; Junge-Hülsing B; Kronawitter U; Sadri I; Matuschke A; Goebel FD
Clin Investig; 1992 Aug; 70(8):665-9. PubMed ID: 1392442
[TBL] [Abstract][Full Text] [Related]
13. Correlates of zidovudine phosphorylation with markers of HIV disease progression and drug toxicity.
Stretcher BN; Pesce AJ; Frame PT; Greenberg KA; Stein DS
AIDS; 1994 Jun; 8(6):763-9. PubMed ID: 8086134
[TBL] [Abstract][Full Text] [Related]
14. Serum levels of soluble CD8, neopterin, beta 2-microglobulin and p24 antigen as indicators of disease progression in children with AIDS on zidovudine therapy.
Siller L; Martin NL; Kostuchenko P; Beckett L; Rautonen J; Cheng SC; Wara DW
AIDS; 1993 Mar; 7(3):369-73. PubMed ID: 8097095
[TBL] [Abstract][Full Text] [Related]
15. Elevated serum calprotectin levels in HIV-infected patients: the calprotectin response during ZDV treatment is associated with clinical events.
Müller F; Frøland SS; Aukrust P; Fagerhol MK
J Acquir Immune Defic Syndr (1988); 1994 Sep; 7(9):931-9. PubMed ID: 7914232
[TBL] [Abstract][Full Text] [Related]
16. Neopterin and interferon-gamma in serum and cerebrospinal fluid of patients with HIV-associated neurologic disease.
Griffin DE; McArthur JC; Cornblath DR
Neurology; 1991 Jan; 41(1):69-74. PubMed ID: 1898675
[TBL] [Abstract][Full Text] [Related]
17. Predictive markers of AIDS dementia complex: CD4 cell count and cerebrospinal fluid concentrations of beta 2-microglobulin and neopterin.
Brew BJ; Dunbar N; Pemberton L; Kaldor J
J Infect Dis; 1996 Aug; 174(2):294-8. PubMed ID: 8699058
[TBL] [Abstract][Full Text] [Related]
18. Elevated neopterin and beta 2-microglobulin levels in blood and cerebrospinal fluid occur early in HIV-1 infection.
Sönnerborg AB; von Stedingk LV; Hansson LO; Strannegård OO
AIDS; 1989 May; 3(5):277-83. PubMed ID: 2504231
[TBL] [Abstract][Full Text] [Related]
19. Neopterin and beta 2-microglobulin as serum markers in a placebo-controlled anti-HIV therapy trial.
Carstens J; Teglbjaerg LS; Black FT
Eur J Clin Chem Clin Biochem; 1995 Sep; 33(9):559-62. PubMed ID: 8611664
[TBL] [Abstract][Full Text] [Related]
20. Close relationships between neopterin and beta-2-microglobulin levels in intravenous drug abusers.
Lin RY; Nygren E; Valinsky J; Lorenzana FG; Ralph H
Int Arch Allergy Appl Immunol; 1990; 91(4):389-93. PubMed ID: 1976599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
